Daewoong Pharmaceutical CEO Park Sung-soo delivers a speech in the course of the GMP certification ceremony for Daewoong’s new stem cell plant in Indonesia on Thursday. (Daewoong Pharma)
South Korean drug maker Daewoong Pharmaceutical has introduced the launch of a brand new stem cell plant in Indonesia, marking the twentieth anniversary of its entry into the Indonesian market. The ability is ready to drive large-scale analysis and improvement initiatives in collaboration with native pharmaceutical and biotech industries, in response to the agency.
The stem cell plant, established by Daewoong Biologics Indonesia — a subsidiary of Daewoong Pharmaceutical — will start full-scale operations following the receipt of the Good Manufacturing Follow certification from the Indonesian Meals and Drug Supervisory Authority.
The plant will present quite a lot of stem cell merchandise, together with umbilical cord-derived stem cells, fat-derived stem cells, exosomes and immune cells. Daewoong highlighted the plant’s means to provide high-quality stem cells for Indonesian sufferers.
The GMP certification ceremony, held on Thursday in Indonesia, was attended by some 150 friends, together with Taruna Ikrar, head of the Meals and Drug Supervisory Authority; Dante Saksono Harbuwono, vice minister of the Ministry of Well being of the Republic of Indonesia; Kim Sang-bong, a senior official at South Korea’s Meals and Drug Security Ministry; Park Soo-Deok, deputy ambassador of South Korea to Indonesia and Lee Jae-guk, vice chair of the Korea Pharmaceutical and Bio-Pharma Producers Affiliation.
Taruna Ikrar, head of the Meals and Drug Supervisory Authority, excursions Daewoong’s new stem cell plant in Indonesia in September. (Daewoong Pharma)
“Daewoong goals to develop alongside Indonesia’s pharmaceutical and biotech sectors as an innovation associate,” Park Sung-soo, Daewoong Pharmaceutical CEO stated on the ceremony. “We’re dedicated to enhancing the standard of life in Indonesia by integrating cutting-edge stem cell expertise.”
Daewoong first entered the Indonesian market in 2005 with the institution of its Jakarta department. In 2012, it based Daewoong Infion as a three way partnership, resulting in the creation of Indonesia’s first biopharmaceutical plant. The corporate’s first biosimilar, epoetin, was permitted and produced in Indonesia in 2017.
Trying forward, Daewoong plans to proceed advancing the pharmaceutical and biotech sectors in Indonesia and fostering native expertise improvement.
“As the primary Korean firm to acquire GMP certification for stem cell processing within the Indonesian market, we are going to deal with advancing analysis, improvement and commercialization of remedies for intractable illnesses and bioregenerative medication,” a Daewoong official stated.
